Patents by Inventor Per Akesson

Per Akesson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190079104
    Abstract: It has been demonstrated that the urinary level of HBP increases in individuals that have a urinary tract infection. Accordingly, the urinary level of HBP in an individual can be used to determine whether or not an individual has a urinary tract infection.
    Type: Application
    Filed: September 21, 2018
    Publication date: March 14, 2019
    Inventors: Lars BJÖRCK, Bertil CHRISTENSSON, Heiko HERWALD, Adam LINDER, Per AKESSON
  • Publication number: 20160252529
    Abstract: It has been demonstrated that the urinary level of HBP increases in individuals that have a urinary tract infection. Accordingly, the urinary level of HBP in an individual can be used to determine whether or not an individual has a urinary tract infection.
    Type: Application
    Filed: May 12, 2016
    Publication date: September 1, 2016
    Inventors: Lars BJÖRCK, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
  • Publication number: 20140187503
    Abstract: It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis.
    Type: Application
    Filed: December 2, 2013
    Publication date: July 3, 2014
    Applicant: Hansa Medical AB
    Inventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
  • Publication number: 20140080754
    Abstract: It has been demonstrated that the level of HBP increases in individuals that have bacterial meningitis. Accordingly, the level of HBP in an individual can be used to determine whether or not an individual has bacterial meningitis.
    Type: Application
    Filed: September 23, 2011
    Publication date: March 20, 2014
    Applicant: HANSA MEDICAL AB
    Inventors: Lars Björck, Bertil Christensson, Adam Linder, Heiko Herwald, Per Åkesson
  • Publication number: 20140080925
    Abstract: It has been demonstrated that the urinary level of HBP increases in individuals that have a urinary tract infection. Accordingly, the urinary level of HBP in an individual can be used to determine whether or not an individual has a urinary tract infection.
    Type: Application
    Filed: February 7, 2012
    Publication date: March 20, 2014
    Applicant: Hansa Medical AB
    Inventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
  • Publication number: 20130252347
    Abstract: It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis.
    Type: Application
    Filed: March 12, 2013
    Publication date: September 26, 2013
    Applicant: Hansa Medical AB
    Inventors: Lars Bjorck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Akesson
  • Publication number: 20100305185
    Abstract: It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis.
    Type: Application
    Filed: June 12, 2008
    Publication date: December 2, 2010
    Inventors: Lars Björck, Bertil Christensson, Heiko Herwald, Adam Linder, Per Åkesson
  • Patent number: 7361750
    Abstract: A protein from Streptococcus pyogenes, serotype M1 has been characterized. This protein, called protein SIC, plays a role in S. pyogenes pathogenicity and virulence. It inhibits hemolysis by interacting with the plasma proteins clusterin, and members of the cystatin protein super family such as histidine rich glycoprotein (HRG). The protein comprises at least one of the following partial amino acid sequences: (a) glu thr tyr thr ser arg asn phe; (b) asp trp ser gly asp asp trp pro glu asp asp trp; (c) arg ser gly val gly leu ser gln tyr gly trp ser; (d) trp ser ser asp lys lys asp glu thr glu asp lyr thr; (e) gly thr gly tyr glu lys arg asp asp trp gly gly pro gly; and (f) lys arg asp asp trp arg gly pro gly his ile pro lys pro. The protein and antibodies specific for the protein can be used in analytical procedures for determining the presence of virulent Streptococcus pyogenes in a sample. The protein can also be used in vaccine compositions.
    Type: Grant
    Filed: February 26, 2003
    Date of Patent: April 22, 2008
    Assignee: Genovis AB
    Inventors: Per Akesson, Lars H. Björck, Anders Sjoholm
  • Publication number: 20060241031
    Abstract: An assay method for an anti-bacterial agent comprising: (a) providing as a first component protein SIC; (b) providing as a second component an antibacterial peptide; (c) contacting the first component with a test substance in the presence of the second component; and (d) determining the interaction or activity of the first component with the second component to determine thereby whether a test substance is an effective anti-bacterial agent.
    Type: Application
    Filed: February 19, 2004
    Publication date: October 26, 2006
    Inventors: Per Akesson, Lars Björck, Anders Sjöholm
  • Publication number: 20060205925
    Abstract: A protein from Streptococcus pyogenes, serotype M1 has been characterized. This protein, called protein SIC, plays a role in S. pyogenes pathogenicity and virulence. It inhibits hemolysis by interacting with the plasma proteins clusterin, and members of the cystatin protein super family such as histidine rich glycoprotein (HRG). The protein, comprises at least one of the following partial amino acid sequences: (a) glu thr tyr thr ser arg asn phe; (b) asp trp ser gly asp asp trp pro glu asp asp trp; (c) arg ser gly val gly leu ser gln tyr gly trp ser; (d) trp ser ser asp lys lys asp glu thr glu asp lys thr; (e) gly thr gly tyr glu lys arg asp asp trp gly gly pro gly; (f) lys arg asp asp trp arg gly pro gly his ile pro lys pro. The protein and antibodies specific for the protein can be used in analytical procedures for determining the presence of virulent Streptococcus pyogenes in a sample. The protein can also be used in vaccine compositions.
    Type: Application
    Filed: May 5, 2006
    Publication date: September 14, 2006
    Applicant: Hansa Medical AB
    Inventors: Per Akesson, Lars Bjorck, Anders Sjoholm
  • Publication number: 20040010117
    Abstract: A protein from Streptococcus pyogenes, serotype M1 has been characterized. This protein, called protein SIC, plays a role in S. pyogenes pathogenicity and virulence. It inhibits hemolysis by interacting with the plasma proteins clusterin, and members of the cystatin protein super family such as histidine rich glycoprotein (HRG). The protein, comprises at least one of the following partial amino acid sequences: (a) glu thr tyr thr ser arg asn phe; (b) asp trp ser gly asp asp trp pro glu asp asp trp; (c) arg ser gly val gly leu ser gln tyr gly trp ser; (d) trp ser ser asp lys lys asp glu thr glu asp lys thr; (e) gly thr gly tyr glu lys arg asp asp trp gly gly pro gly; (f) lys arg asp asp trp arg gly pro gly his ile pro lys pro. The protein and antibodies specific for the protein can be used in analytical procedures for determining the presence of virulent Streptococcus pyogenes in a sample. The protein can also be used in vaccine compositions.
    Type: Application
    Filed: February 26, 2003
    Publication date: January 15, 2004
    Applicant: Actinova, Ltd.
    Inventors: Per Akesson, Lars Bjorck, Anders Sjoholm